AstraZeneca
AZN and Bristol-Myers
Squibb Company BMY today announced results from a Phase III
study evaluating dapagliflozin in adult patients with type 2 diabetes
who were inadequately controlled on combination treatment with metformin
plus sulfonylurea. Patients treated with dapagliflozin 10 mg as an
add-on therapy to metformin plus sulfonylurea demonstrated significant
improvements in glycosylated hemoglobin levels (HbA1c) and, among key
secondary endpoints, significant reductions in fasting plasma glucose
(FPG) and in body weight compared to placebo at 24 weeks. Significant
improvements were also observed in seated systolic blood pressure (SBP)
at eight weeks in patients treated with dapagliflozin compared to
placebo. The results were presented today at the 49th Annual
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in